HDAC inhibitor with tamoxifen treatment reduced tumor cell resistance in estrogen receptor-positive breast cancer. Critical pathway by which tumors become tamoxifen resistant identified. Early introduction of HDAC inhibitor with tamoxifen is key. SAN FRANCISCO — Researchers have shown how estrogen...
Sun, Nov 13 2011
Filed under: Filed under: Press Releases, Research, Treatment, Breast Cancer, Conference, Cancer, Media Materials, AACR, American Association for Cancer Research, meeting, National Cancer Institute, NCI, estrogen receptor-positive breast cancer, Molecular Targets, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Cancer Therapeutics, EORTC, European Organisation for Research and Treatment of Cancer, HDAC inhibitor, tamoxifen, ER-positive breast cancer, AKT, Dr. Pamela N. Munster